Mutations in 23S rRNA confer resistance against azithromycin in Pseudomonas aeruginosa

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 8, 2012, Pages 4519-4521

  Marvig, Rasmus Lykke ^a   Søndergaard, Mette S R ^a   Damkiær, Søren ^a   Høiby, Niels ^b   Johansen, Helle Krogh ^b   Molin, Søren ^a   Jelsbak, Lars ^a  

^a TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; RNA 23S;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; CYSTIC FIBROSIS; GENE MUTATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; POINT MUTATION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RNA, BACTERIAL; RNA, RIBOSOMAL, 23S;

EID: 84864387258     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00630-12     Document Type: Article

References (15)

1. Cai Y, et al. 2011. Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review. J. Antimicrob. Chemother. 66:968-978.
2. Glansdorp FG, et al. 2008. Using chemical probes to investigate the sub-inhibitory effects of azithromycin. Org. Biomol. Chem. 6:4120-4124.
3. Hansen CR, Pressler T, Koch C, Høiby N. 2005. Long-term azithromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study. J. Cyst. Fibros. 4:35-40. (Pubitemid 40347775)
4. Heeb S, et al. 2000. Small, stable shuttle vectors based on the minimal pVS1 replicon for use in gram-negative, plant-associated bacteria. Mol. Plant Microbe Interact. 13:232-237. (Pubitemid 30061607)
5. Herrero M, de Lorenzo V, Timmis KN. 1990. Transposon vectors containing non-antibiotic resistance selection markers for cloning and stable chromosomal insertion of foreign genes in gram-negative bacteria. J. Bacteriol. 172:6557-6567. (Pubitemid 20372801)
6. Høiby N, Frederiksen B. 2000. Microbiology of cystic fibrosis, p 83-107. In Hodson M, Geddes D (ed), Cystic fibrosis, 2nd ed. Arnold, London, United Kingdom.
7. Holloway BW, Krishnapillai V, Morgan AF. 1979. Chromosomal genetics of Pseudomonas. Microbiol. Rev. 43:73-102. (Pubitemid 9169387)
8. Kataja J, Huovinen P, Skurnik M, The Finnish Study Group for Antimicrobial Resistance, Seppälä H. 1999. Erythromycin resistance genes in group A streptococci in Finland. Antimicrob. Agents Chemother. 43:48-52. (Pubitemid 29069198)
9. Köhler T, Dumas JL, Van Delden C. 2007. Ribosome protection prevents azithromycin-mediated quorum-sensing modulation and stationaryphase killing of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 51:4243-4248. (Pubitemid 350209872)
10. Li H, et al. 2009. The sequence alignment/map format and SAMtools. Bioinformatics 25:2078-2079.
11. Ross JI, et al. 1990. Inducible erythromycin resistance in staphylococci is encoded by a member of the ATP-binding transport super-gene family. Mol. Microbiol. 4:1207-1214. (Pubitemid 120005382)
12. Tait-Kamradt A, et al. 2000. Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrob. Agents Chemother. 44:2118-2125. (Pubitemid 30484435)
13. Vester B, Douthwaite S. 2001. Macrolide resistance conferred by base substitutions in 23S rRNA. Antimicrob. Agents Chemother. 45:1-12. (Pubitemid 32039086)
14. Wilms EB, Touw DJ, Heijerman HG. 2008. Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients. J. Cyst. Fibros. 7:79-84.
15. Yang L, et al. 2011. Evolutionary dynamics of bacteria in a human host environment. Proc. Natl. Acad. Sci. U. S. A. 108:7481-7486.